{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:49:58Z","timestamp":1783637398695,"version":"3.55.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":622,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Janus Kinase (JAK) inhibition has recently demonstrated therapeutic efficacy in both restoring hair growth and resolving inflammation in Alopecia Areata (AA). These effects are dose dependent and mainly efficacious at ranges close to a questionable risk profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We explored the possibility to separate the beneficial and adverse effects of JAK inhibition by selectively inhibiting JAK1 and thereby avoiding side effects associated with JAK2 blockade.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The C3H\/HeJ mouse model of AA was used to demonstrate therapeutic efficacy in vivo with different regimens of a selection of JAK inhibitors in regards to systemic versus local drug exposure. Human peripheral blood lymphocytes were stimulated in vitro to demonstrate translation to the human situation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrate that selective inhibition of JAK1 produces fast resolution of inflammation and complete restoration of hair growth in the C3H\/HeJ mouse model of AA. Furthermore, we show that topical treatment does not restore hair growth and that treatment needs to be extended well beyond that of restored hair growth in order to reach treatment-free remission. For translatability to human disease, we show that cytokines involved in AA pathogenesis are similarly inhibited by selective JAK1 and pan-JAK inhibition in stimulated human peripheral lymphocytes and specifically in CD8+ T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates that systemic exposure is required for efficacy in AA and we propose that a selective JAK1 inhibitor will offer a treatment option with a superior safety profile to pan-JAK inhibitors for these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/ski2.209","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T11:04:41Z","timestamp":1674990281000},"source":"Crossref","is-referenced-by-count":12,"title":["Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata"],"prefix":"10.1093","volume":"3","author":[{"given":"Johan","family":"Mattsson","sequence":"first","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Israelsson","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bj\u00f6rhall","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Fahl\u00e9n","family":"Yrlid","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Th\u00f6rn","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Thor\u00e9n","sequence":"additional","affiliation":[{"name":"Animal Science and Technologies, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie Anders\u00e9n","family":"Toledo","sequence":"additional","affiliation":[{"name":"Animal Science and Technologies, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Jinton","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"\u00d6berg","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Wingren","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Tapani","sequence":"additional","affiliation":[{"name":"Early Biometrics & Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya G.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Skogberg","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders J.","family":"Lundqvist","sequence":"additional","affiliation":[{"name":"Drug Metabolism & Pharmacokinetics, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Hendrickx","sequence":"additional","affiliation":[{"name":"Drug Metabolism & Pharmacokinetics, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Cavallin","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"\u00d6sterlund","sequence":"additional","affiliation":[{"name":"The Discovery Sciences Unit, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Grimster","sequence":"additional","affiliation":[{"name":"Chemistry, Oncology R&D, AstraZeneca , Waltham, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Medicinal Chemistry, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"\u00c5strand","sequence":"additional","affiliation":[{"name":"Bioscience, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"issue":"2","key":"2025010818091300800_ski2209-bib-0001","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"16","key":"2025010818091300800_ski2209-bib-0002","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/nejmra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0003","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/exd.12209","article-title":"What causes alopecia areata","volume":"22","author":"McElwee","year":"2013","journal-title":"Exp Dermatol"},{"issue":"7","key":"2025010818091300800_ski2209-bib-0004","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","article-title":"Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States","volume":"149","author":"Huang","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2025010818091300800_ski2209-bib-0005","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/ccid.s53985","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7302","key":"2025010818091300800_ski2209-bib-0006","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"2025010818091300800_ski2209-bib-0007","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/itt.s266409","article-title":"Alopecia areata: an autoimmune disease of multiple players","volume":"10","author":"Suchonwanit","year":"2021","journal-title":"ImmunoTargets Ther"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0008","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","article-title":"Comorbidities in alopecia areata: a systematic review and meta-analysis","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0009","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0010","first-page":"1077","article-title":"Evidence that the bulge region is a site of relative immune privilege in human hair follicles","volume":"159","author":"Meyer","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"2025010818091300800_ski2209-bib-0011","first-page":"541","article-title":"Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb?","volume":"66","author":"Paus","year":"1993","journal-title":"Yale J Biol Med"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0012","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","article-title":"Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack","volume":"128","author":"Ito","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0013","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/s0002-9440(10)63151-3","article-title":"Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model","volume":"164","author":"Ito","year":"2004","journal-title":"Am J Pathol"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0014","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1189\/jlb.0413196","article-title":"Tolerance induction by hair-specific keratins in murine alopecia areata","volume":"94","author":"Erb","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0015","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1021\/pr100422u","article-title":"Trichohyalin is a potential major autoantigen in human alopecia areata","volume":"9","author":"Leung","year":"2010","journal-title":"J Proteome Res"},{"issue":"8","key":"2025010818091300800_ski2209-bib-0016","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.jid.2016.04.004","article-title":"Identification of autoantigen epitopes in alopecia areata","volume":"136","author":"Wang","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2025010818091300800_ski2209-bib-0017","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1172\/jci31942","article-title":"Lymphocytes, neuropeptides, and genes involved in alopecia areata","volume":"117","author":"Gilhar","year":"2007","journal-title":"J Clin Invest"},{"issue":"12","key":"2025010818091300800_ski2209-bib-0018","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0019","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"8","key":"2025010818091300800_ski2209-bib-0020","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0021","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0022","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000445182","article-title":"Transient efficacy of tofacitinib in alopecia areata universalis","volume":"8","author":"Anzengruber","year":"2016","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"2025010818091300800_ski2209-bib-0023","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"15","key":"2025010818091300800_ski2209-bib-0024","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"15","key":"2025010818091300800_ski2209-bib-0025","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0026","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0027","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2340\/00015555-2491","article-title":"Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman","volume":"97","author":"Mrowietz","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2025010818091300800_ski2209-bib-0028","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2147\/ccid.s309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0029","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"6","key":"2025010818091300800_ski2209-bib-0030","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"18","key":"2025010818091300800_ski2209-bib-0031","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/nejmoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0032","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0033","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0034","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0035","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"2025010818091300800_ski2209-bib-0036","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025010818091300800_ski2209-bib-0037","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"2025010818091300800_ski2209-bib-0038","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0039","doi-asserted-by":"publisher","first-page":"621","DOI":"10.25259\/ijdvl_975_19","article-title":"Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and meta-analysis","volume":"87","author":"Yu","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0040","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1021\/acs.jmedchem.9b01392","article-title":"Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-y l]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a potent and selective Janus kinase 1 inhibitor","volume":"63","author":"Su","year":"2020","journal-title":"J Med Chem"},{"issue":"12","key":"2025010818091300800_ski2209-bib-0041","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1021\/acs.jmedchem.8b00076","article-title":"Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors","volume":"61","author":"Grimster","year":"2018","journal-title":"J Med Chem"},{"key":"2025010818091300800_ski2209-bib-0042","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.2147\/dddt.s354291","article-title":"Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0043","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1021\/ol900350k","article-title":"Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction","volume":"11","author":"Lin","year":"2009","journal-title":"Org Lett"},{"issue":"12","key":"2025010818091300800_ski2209-bib-0044","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0045","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1523-1747.1998.00380.x","article-title":"Experimental induction of alopecia areata-like hair loss in C3H\/HeJ mice using full-thickness skin grafts","volume":"111","author":"McElwee","year":"1998","journal-title":"J Invest Dermatol"},{"key":"2025010818091300800_ski2209-bib-0046","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000131749","article-title":"Alopecia areata","volume":"10","author":"King","year":"2008","journal-title":"Curr Dir Autoimmun"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0047","first-page":"392","article-title":"Surgical methods for full-thickness skin grafts to induce alopecia areata in C3H\/HeJ mice","volume":"63","author":"Silva","year":"2013","journal-title":"Comp Med"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0048","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","article-title":"RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues","volume":"14","author":"Wang","year":"2012","journal-title":"J Mol Diagn"},{"key":"2025010818091300800_ski2209-bib-0049","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ebiom.2016.03.036","article-title":"Molecular signatures define alopecia areata subtypes and transcriptional biomarkers","volume":"7","author":"Jabbari","year":"2016","journal-title":"EBioMedicine"},{"issue":"12","key":"2025010818091300800_ski2209-bib-0050","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"15","key":"2025010818091300800_ski2209-bib-0051","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"2025010818091300800_ski2209-bib-0052","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1749-6632.1971.tb46890.x","article-title":"Factors affecting drug metabolism","volume":"179","author":"Gillette","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"2025010818091300800_ski2209-bib-0053","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1749-6632.1973.tb20464.x","article-title":"Overview of drug-protein binding","volume":"226","author":"Gillette","year":"1973","journal-title":"Ann N Y Acad Sci"},{"key":"2025010818091300800_ski2209-bib-0054","doi-asserted-by":"publisher","first-page":"928030","DOI":"10.1155\/2010\/928030","article-title":"Cytokines and other mediators in alopecia areata","volume":"2010","author":"Gregoriou","year":"2010","journal-title":"Mediators Inflamm"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0055","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1172\/jci0215786","article-title":"JAK-STAT signaling in asthma","volume":"109","author":"Pernis","year":"2002","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"2025010818091300800_ski2209-bib-0056","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0057","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0058","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13543776.2017.1252753","article-title":"Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1","volume":"27","author":"Kettle","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0059","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/13543776.2017.1252754","article-title":"Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2","volume":"27","author":"Kettle","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"2025010818091300800_ski2209-bib-0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/09546634.2016.1277179","article-title":"Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature","author":"Samadi","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"2025010818091300800_ski2209-bib-0061","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2567.2006.02429.x","article-title":"Prolonged exposure of naive CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length","volume":"119","author":"Wallace","year":"2006","journal-title":"Immunology"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0062","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat Immunol"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0063","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.4049\/jimmunol.170.10.5018","article-title":"IL-15 promotes the survival of naive and memory phenotype CD8+ T cells","volume":"170","author":"Berard","year":"2003","journal-title":"J Immunol"},{"issue":"11","key":"2025010818091300800_ski2209-bib-0064","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/nm.3962","article-title":"Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma","volume":"21","author":"Adachi","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0065","doi-asserted-by":"publisher","first-page":"5170","DOI":"10.4049\/jimmunol.1003961","article-title":"The basis of distinctive IL-2- and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development","volume":"187","author":"Castro","year":"2011","journal-title":"J Immunol"},{"issue":"6205","key":"2025010818091300800_ski2209-bib-0066","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1126\/science.1254803","article-title":"T cell memory. Skin-resident memory CD8(+) T cells trigger a state of tissue-wide pathogen alert","volume":"346","author":"Ariotti","year":"2014","journal-title":"Science"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0067","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.0022-202x.2004.23580.x","article-title":"Alopecia areata induced in C3H\/HeJ mice by interferon-gamma: evidence for loss of immune privilege","volume":"124","author":"Gilhar","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2025010818091300800_ski2209-bib-0068","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"Freyschmidt-Paul","year":"2006","journal-title":"Br J Dermatol"},{"issue":"7","key":"2025010818091300800_ski2209-bib-0069","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"issue":"19","key":"2025010818091300800_ski2209-bib-0070","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"2025010818091300800_ski2209-bib-0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173505","article-title":"Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"885","author":"Covington","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"2025010818091300800_ski2209-bib-0072","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1021\/jm300248q","article-title":"A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779","volume":"55","author":"Dugan","year":"2012","journal-title":"J Med Chem"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0073","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1021\/jm1011319","article-title":"Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)p yrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak\/Stat pathway","volume":"54","author":"Ioannidis","year":"2011","journal-title":"J Med Chem"},{"issue":"3","key":"2025010818091300800_ski2209-bib-0074","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12154-009-0023-9","article-title":"Measuring and interpreting the selectivity of protein kinase inhibitors","volume":"2","author":"Smyth","year":"2009","journal-title":"J Chem Biol"},{"issue":"6","key":"2025010818091300800_ski2209-bib-0075","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"2025010818091300800_ski2209-bib-0076","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1203475417716363","article-title":"A case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"9","key":"2025010818091300800_ski2209-bib-0077","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0078","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.4049\/jimmunol.1501798","article-title":"CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata","volume":"197","author":"Dai","year":"2016","journal-title":"J Immunol"},{"issue":"3","key":"2025010818091300800_ski2209-bib-0079","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/1523-1747.ep12395398","article-title":"Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene","volume":"103","author":"Tarlow","year":"1994","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2025010818091300800_ski2209-bib-0080","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.1365-2370.2002.00271.x","article-title":"Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: strong severity association and possible gene interaction","volume":"29","author":"Tazi-Ahnini","year":"2002","journal-title":"Eur J Immunogenet"},{"issue":"10","key":"2025010818091300800_ski2209-bib-0081","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"2025010818091300800_ski2209-bib-0082","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2025010818091300800_ski2209-bib-0083","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.4049\/jimmunol.172.4.2171","article-title":"Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion","volume":"172","author":"Wong","year":"2004","journal-title":"J Immunol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ski2.209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ski2.209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/3\/ski2.209\/59729341\/skinhd_3_3_e209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/3\/ski2.209\/59729341\/skinhd_3_3_e209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:09:24Z","timestamp":1736359764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.209\/7755541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.209","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,1,29]]},"article-number":"ski2.209"}}